Industry
Biotechnology
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Loading...
Open
7.14
Mkt cap
1.2B
Volume
9M
High
7.33
P/E Ratio
-3.01
52-wk high
23.86
Low
6.81
Div yield
N/A
52-wk low
3.53
Portfolio Pulse from Benzinga Newsdesk
June 14, 2024 | 6:13 pm
Portfolio Pulse from Benzinga Newsdesk
June 14, 2024 | 6:07 pm
Portfolio Pulse from Benzinga Newsdesk
June 14, 2024 | 5:27 pm
Portfolio Pulse from Benzinga Newsdesk
June 12, 2024 | 2:40 pm
Portfolio Pulse from Benzinga Insights
June 10, 2024 | 4:31 pm
Portfolio Pulse from Lekha Gupta
June 09, 2024 | 6:29 pm
Portfolio Pulse from Benzinga Newsdesk
June 07, 2024 | 6:54 pm
Portfolio Pulse from Avi Kapoor
June 07, 2024 | 5:07 pm
Portfolio Pulse from Vandana Singh
June 07, 2024 | 4:05 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.